Smack in the middle of the American Society of Hematology (ASH) annual meeting in San Diego, presenter Spark Therapeutics Inc. disclosed a licensing deal that harnesses the synthetic vaccine particles (SVP) platform technology developed by Selecta Biosciences Inc. for co-administration with Spark's gene therapy program in up to five targets, beginning with factor VIII (FVIII) in hemophilia A.